co-infusion
Showing 1 - 25 of >10,000
Dexmedetomidine, Esketamine, Postoperative Pain and Recovery Quality Trial in Anqing (Dexmedetomidine infusion,
Recruiting
- Dexmedetomidine, Esketamine, Postoperative Pain and Recovery Quality
- Dexmedetomidine infusion
- +2 more
-
Anqing, Anhui, ChinaDepartment of Anqing Hospital Anesthesiology
May 3, 2022
Lidocaine, Dexmedetomidine, Quality of Recovery(QoR-40), Preoperative and Postoperative Trial in Anqing (Co-administration
Completed
- Lidocaine
- +2 more
- Co-administration Lidocaine and Dexmedetomidine
- +3 more
-
Anqing, Anhui, ChinaDepartment of Anqing Hospital Anesthesiology
Mar 8, 2022
Hepatocellular Carcinoma Trial in Wuhan (Nocardia rubra cell wall skeleton, Hepatic arterial infusion chemo, Lenvatinib)
Recruiting
- Hepatocellular Carcinoma
- Nocardia rubra cell wall skeleton
- +3 more
-
Wuhan, Hubei, ChinaHepatic Surgery Center, Tongji Hospital, Tongji Medical College,
Sep 5, 2022
Systemic Lupus Erythematosus Trial (CD19 CAR-T cell infusion)
Not yet recruiting
- Systemic Lupus Erythematosus
- CD19 CAR-T cell infusion
- (no location specified)
Oct 24, 2023
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for
Recruiting
- Hepatocellular Carcinoma Non-resectable
- HAIC
- +8 more
-
Quanzhou, Fujian, China
- +1 more
Jan 26, 2023
Hematologic Malignancies Trial in Zhengzhou (RD13-02 cell infusion)
Recruiting
- Hematologic Malignancies
- RD13-02 cell infusion
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Jun 26, 2023
Carcinoma Trial (Intravenous infusion anti-CEA-CAR-T cell)
Not yet recruiting
- Carcinoma
- Intravenous infusion anti-CEA-CAR-T cell
- (no location specified)
Aug 22, 2023
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA), Severe Aplastic Anemia (SAA) Trial run by the NHLBI (Umbilical Cord
Completed
- Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)
- Severe Aplastic Anemia (SAA)
- Umbilical Cord Blood
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 16, 2021
Stage IV Gastric Cancer With Metastasis Trial (Camrelizumab; Nab-paclitaxel; S-1)
Not yet recruiting
- Stage IV Gastric Cancer With Metastasis
- Camrelizumab; Nab-paclitaxel; S-1
- (no location specified)
Jul 5, 2022
Multiple Myeloma, Primary Plasma Cell Leukemia Trial in Shanghai (Experimental: CAR-T cells Infusion)
Not yet recruiting
- Multiple Myeloma
- Primary Plasma Cell Leukemia
- Experimental: CAR-T cells Infusion
-
Shanghai, ChinaShanghai Changzheng Hospital
Apr 20, 2023
Hepatocellular Carcinoma Trial in Jinan (Camrelizumab)
Recruiting
- Hepatocellular Carcinoma
-
Jinan, Shandong, ChinaShandong Cancer Hospital and Institute
Nov 16, 2022
Tumors, Hematologic Tumors, Hematologic Diseases Trial in Hefei (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +2 more
- RD13-02 cell infusion
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of University of Science and Techn
Jun 5, 2023
C-staged Hepatocellular Carcinoma in BCLC Classification Trial in Guangzhou (Hepatic Arterial Infusion combined with Apatinib
Recruiting
- C-staged Hepatocellular Carcinoma in BCLC Classification
- Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 3, 2022
Hypotension Symptomatic, Vasoconstriction, Cesarean Section Complications Trial in Athens (phenylephrine infusion,
Completed
- Hypotension Symptomatic
- +3 more
- phenylephrine infusion
- +2 more
-
Athens, GreeceAretaieion University Hospital
Jun 13, 2021
Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)
Not yet recruiting
- Solid Tumor
- Intravenous infusion anti-HER2-CAR-T cell
-
Shenyang, Liaoning, ChinaPhase I Clinical Trials Center Of The First Hospital of China Me
Oct 30, 2023
Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +2 more
- RD13-02 cell infusion
-
Xuzhou, Jiangsu, ChinaAffiliated hospital of Xuzhou medical college
Jun 7, 2023
Advanced Hepatocellular Carcinoma Trial in Hangzhou (CT0180 Cells)
Recruiting
- Advanced Hepatocellular Carcinoma
- CT0180 Cells
-
Hangzhou, Zhejiang, ChinaFirst affiliated hospital, Zhejiang University
Jan 27, 2023
Tumors, Hematologic Tumors, Tumors by Site Trial in Wuhan (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +3 more
- RD13-02 cell infusion
-
Wuhan, Hubei, ChinaUnion Hospital, Huazhong University of Science and Technology
Jun 8, 2023
Colon Mucous, Colonoscopy Trial in Taoyuan (CO2, Water, 50% saline)
Recruiting
- Colon Mucous
- Colonoscopy
- CO2
- +3 more
-
Taoyuan, TaiwanEvergreen General Hospital
Jan 18, 2022
Tumors, Hematologic Tumors, Tumors by Site Trial in Hangzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +3 more
- RD13-02 cell infusion
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Feb 6, 2023
Rheumatoid Arthritis Trial (CT-P47, EU-approved RoActemra)
Not yet recruiting
- Rheumatoid Arthritis
- CT-P47
- EU-approved RoActemra
- (no location specified)
Aug 16, 2022
C-staged Hepatocellular Carcinoma in BCLC Classification Trial in Guangzhou, Guanzhou, Changsha (Hepatic Arterial Infusion
Recruiting
- C-staged Hepatocellular Carcinoma in BCLC Classification
- Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
- Apatinib combined with Camrelizumab
-
Guangzhou, Guangdong, China
- +4 more
Jun 15, 2022
Relapsed/Refractory Multiple Myeloma Trial in Wuhan (IBI346)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
-
Wuhan, Hu Bei, ChinaTongji Hospital, Tongji Medical College, Huazhong University of
Feb 23, 2022
Hypotension, Obstetric Anesthesia Problems, Cesarean Section Complications Trial in Athens (norepinephrine infusion and colloid
Completed
- Hypotension
- +4 more
- norepinephrine infusion and colloid preloading (NOR-COL)
- norepinephrine infusion and crystalloid co-loading (NOR-CRYST)
-
Athens, Greece
- +1 more
Jun 13, 2021